14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZBIO vs VERA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ZBIO Overall Winner
6-Pillar Tally: ZBIO 2 – 2 VERA (2 Tie)
Matrix Metrics: ZBIO 3 – 4 VERA
As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Vera Therapeutics, Inc. (VERA) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas VERA carries 45.9/100 (HOLD) at $26.97 (N/M Forward P/E, -4160.1% operating margin).
Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. VERA 45.9/100 HOLD) and 1.16β · 59% Vol risk profile, whereas VERA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VERA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs VERA. Trailing 12-month operating profitability (ZBIO -2747.5% vs VERA -4160.1%) and valuation multiples (ZBIO N/M vs VERA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
VERA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -4160.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZBIO vs VERA Key Questions & Quantitative Answers
As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Vera Therapeutics, Inc. (VERA) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas VERA carries 45.9/100 (HOLD) at $26.97 (N/M Forward P/E, -4160.1% operating margin). Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. VERA 45.9/100 HOLD) and 1.16β · 59% Vol risk profile, whereas VERA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VERA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VERA leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with VERA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $10M TTM revenue (67.9% gross margin, -4160.1% operating margin). On trailing 12-month operating scale, ZBIO generates $11M in USD-normalized revenue versus $10M for VERA. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VERA.
ZBIO and VERA trade at balanced relative valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VERA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus VERA (-113.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, VERA carries 108.9% implied volatility (68th %ile, Elevated (60th–80th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.11β · 57% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.